April 27, 2021
Kyorin Pharmaceutical has obtained the distribution rights to MSD’s refractory cough medicine gefapixant in Japan, which is currently pending approval, the two companies said on April 26. Gefapixant, an oral selective P2X3 receptor antagonist, was filed by MSD, the Japan...read more